KMT2A and acute myeloid leukemia: Early-phase clinical trial data indicate that the tranylcypromine-derivative LSD1 inhibitor ORY-1001 induces morphologic blast cell differentiation and differentiation syndromes in patients with MLL-translocated AML (Somervaille et al., 2016).